The ability of antiviral formulation ViruSAL to inhibit SARS-CoV-2 infectivity biorxivpreprint ucddublin antiviral SARSCoV2 COVID19 coronavirus covid
By Dr. Chinta SidharthanOct 12 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to the bioRxiv* preprint server, researchers from Ireland used human bronchial epithelium models to evaluate the ability of a novel proprietary formulation called ViruSAL to inhibit severe acute respiratory syndrome coronavirus 2 infections.
Antivirals administered intranasally as prophylactics or to lower viral shedding have the potential to provide adjunct therapy along with vaccines and orally administered antivirals. Therefore, developing intranasally administered antivirals that inhibit SARS-CoV-2 infections in the ciliated bronchial epithelia could prevent infections from emergent variants.
Air-liquid interface cultured human bronchial epithelial cells were used to detect the inhibition of SARS-CoV-2 infection in the ciliated surface of the epithelial cells by different concentrations of ViruSAL. Additionally, the ability of ViruSAL to inhibit SARS-CoV-2 in pre- and post-infection ALI-cultured bronchial epithelial cells was also measured. Cell viability after ViruSAL treatment was assessed using 3--2,5-diphenyl-2H-tetrazolium bromide assay.
Transmission electron microscopy images showed no evidence of viral assembly in the endoplasmic reticulum Golgi intermediate compartments of infected VeroE6 cells treated with 3% ViruSAL for two minutes while untreated and control-treated SARS-CoV-2 infected cells revealed virus-like particles in their ERGICs.
No adverse reactions or clinical signs of toxicity were reported in any rat models after the intranasal administration of ViruSAL. The body weights and appetites of all the animals were observed to be normal, and there was no difference in the lung weights of the euthanized test and control group animals.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
RNA-dependent RNA polymerase inhibitors in COVID-19 therapyA new paper reviews current knowledge of RdRp inhibitors that could be developed further to provide broadly effective antivirals against SARS-CoV-2 in particular and CoVs in general.
Read more »
Immune-mediated inflammatory diseases following COVID-19Immune-mediated inflammatory diseases following COVID-19 medrxivpreprint unibirmingham COVID19 SARSCoV2 InflammatoryDisease
Read more »
Timely COVID-19 boosters may prevent care facility outbreaksTimely COVID-19 boosters may prevent care facility outbreaks rivm COVID19 coronavirus covid vaccine vaccination booster
Read more »
What is the effect of COVID-19 vaccination in pregnant and postpartum women infected with different SARS-CoV-2 variants?What is the effect of COVID-19 vaccination in pregnant and postpartum women infected with different SARS-CoV-2 variants? medrxivpreprint Pregnancy SARSCoV2 COVID19 Variants
Read more »
What is the association of pneumococcal carriage with SARS-CoV-2 infection?What is the association of pneumococcal carriage with SARS-CoV-2 infection? medrxivpreprint UCBerkeley YaleSPH SARSCoV2 COVID19 coronavirus covid infection
Read more »
A novel molecularly imprinted polypyrrole electrode for diagnosing COVID-19A recent study examines the interaction between the SARS-CoV-2 spike glycoprotein through the use of a molecularly imprinted polypyrrole electrode.
Read more »